TokenPost·
Ionis Shares Fall About 27% After Tryngolza Sales Forecast Cut
Ionis lowered its 2026 sales outlook for the drug to about $50 million from $100 million to $110 million, despite third-quarter results that beat expectations.
More news
- The DefiantSolana Hits Four-Week Low as Losses Outpace Bitcoin
- The BlockMoody’s and Chainlink test cross-chain credit ratings distribution
- TokenPostJustice Department Takes Over Megaspeed Chip Probe From Commerce
- TokenPostBitcoin Falls Below 73,000 USDT as 24-Hour Drop Reaches 3.2%
- TokenPostHonda Plans $3 Billion Ohio Plant With Capacity for 240,000 Vehicles
- TokenPostEthena Falls 4.69% in One Hour to $0.1483 on Binance Spot